Takeda snags expanded pediatric approval for rare genetic disorder drug
The FDA on Friday approved Takeda’s supplement to expand the use of Takhzyro, a hereditary angioedema (HAE) drug acquired as part of its $62 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
